Shield Therapeutics plc
SHIEF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $32 | $13 | $5 | $2 |
| % Growth | 145.9% | 187.7% | 199.5% | – |
| Cost of Goods Sold | $17 | $9 | $3 | $1 |
| Gross Profit | $15 | $4 | $2 | $1 |
| % Margin | 46.4% | 30.8% | 44.7% | 35.5% |
| R&D Expenses | $2 | $2 | $1 | $1 |
| G&A Expenses | $11 | $15 | $11 | $20 |
| SG&A Expenses | $35 | $37 | $31 | $20 |
| Sales & Mktg Exp. | $24 | $22 | $20 | $14 |
| Other Operating Expenses | $1 | -$4 | $11 | $0 |
| Operating Expenses | $38 | $35 | $43 | $21 |
| Operating Income | -$23 | -$31 | -$41 | -$20 |
| % Margin | -71.1% | -239.4% | -904.7% | -1,336% |
| Other Income/Exp. Net | -$4 | -$1 | $0 | $0 |
| Pre-Tax Income | -$27 | -$32 | -$41 | -$20 |
| Tax Expense | $1 | $1 | $0 | -$0 |
| Net Income | -$27 | -$33 | -$50 | -$20 |
| % Margin | -84.5% | -254.4% | -1,094.5% | -1,295.5% |
| EPS | -0.03 | -0.046 | -0.21 | -0.092 |
| % Growth | 34.9% | 78% | -128.5% | – |
| EPS Diluted | -0.03 | -0.046 | -0.21 | -0.092 |
| Weighted Avg Shares Out | 906 | 723 | 238 | 210 |
| Weighted Avg Shares Out Dil | 906 | 723 | 238 | 210 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $0 | $0 |
| Interest Expense | $4 | $1 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $2 | $2 |
| EBITDA | -$21 | -$30 | -$25 | -$19 |
| % Margin | -66.1% | -231.5% | -539.6% | -1,234.6% |